Detected ·
CREATE Medicines
——
CREATE Medicines closed a $122M Series B financing round co-led by Newpath Partners, ARCH Venture Partners, and Hatteras Venture Partners to advance their in vivo CAR-T therapy platform for autoimmune diseases and cancer.
- Website
- createmedicines.com
- Amount
- —
- Stage
- —
- Event
- Funding round
- Detected
- 2026-05-14 16:12:14 UTC
- Signal ID
- 733cfde1-4ce3-43a6-a123-bd3720b6e42d
As the API returns it
{
"id": "733cfde1-4ce3-43a6-a123-bd3720b6e42d",
"created_at": "2026-05-14T16:12:14.074257Z",
"company_name": "CREATE Medicines",
"company_website_url": "createmedicines.com",
"company_linkedin_url": "https://www.linkedin.com/company/createmedicines",
"event_type": "funding",
"funding_amount": null,
"funding_currency": null,
"funding_stage": null,
"message": "*CREATE Medicines closed a $122M Series B financing round co-led by Newpath Partners, ARCH Venture Partners, and Hatteras Venture Partners to advance their in vivo CAR-T therapy platform for autoimmune diseases and cancer.*"
}